We are Hiring

Vice President,

Clinical Pharmacology

Vice President, Clinical Pharmacology

The Vice President of Clinical Pharmacology at Bicara Therapeutics will play a critical role in leading and shaping the company’s clinical pharmacology strategy, with a focus on advancing our oncology pipeline. You will be responsible for overseeing the design, development, and execution of clinical pharmacology studies, ensuring they align with regulatory requirements and support the progression of our investigational therapies through clinical trials. This is a leadership position that requires close collaboration with cross-functional teams, including clinical development, regulatory affairs, and project management. Massachusetts-based candidates follow a hybrid schedule, working in our Boston office three days per week. Candidates located outside the Boston area follow a hybrid model that includes one on-site visit per month.

Apply Now
Dyne

Position Responsibilities

  • Leadership & Strategy: Lead and manage the clinical pharmacology team to drive the clinical development strategy and ensure pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interaction assessments are integrated into all stages of clinical trials.
  • Clinical Study Design: Develop and oversee the design and implementation of clinical pharmacology studies (e.g., dose escalation, PK/PD modeling) for oncology drug candidates, ensuring optimal dosing strategies and evidence generation.
  • Regulatory Compliance: Provide pharmacology expertise and strategic guidance to ensure clinical studies meet regulatory requirements and align with global health authority expectations (FDA, EMA, etc.).
  • Collaboration: Work cross-functionally with clinical development, medical affairs, regulatory affairs, and translational medicine teams to support the design, execution, and interpretation of clinical studies.
  • Data Analysis & Interpretation: Oversee the analysis and interpretation of clinical pharmacology data to provide insights into dose optimization, safety profiles, and clinical pharmacology models.
  • External Relationships: Foster relationships with external scientific and clinical experts, KOLs (Key Opinion Leaders), and regulatory agencies to ensure best practices and keep up to date with industry trends.
  • Team Development: Build, mentor, and grow a high-performing clinical pharmacology team while fostering a culture of collaboration, innovation, and excellence.
  • Clinical Trial Management: Work closely with project management teams to ensure the timely execution of clinical trials, manage budgets, and ensure resources are appropriately allocated.
  • Publications & Presentations: Contribute to scientific publications and presentations at industry conferences to enhance the company’s scientific reputation and communicate clinical pharmacology findings.
Apply Now

Preferred Qualifications

Apply Now

Know About

About
Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types.

Product
Pipeline

Bicara Therapeutics is advancing a focused pipeline built around its proprietary bifunctional antibody platform, designed to target tumor-driving pathways while modulating the immune microenvironment. The lead candidate, BCA101 (ficerafusp alfa), is a first-in-class EGFR-targeting and TGF-β–trapping antibody currently in a pivotal Phase 2/3 trial (FORTIFI-HN01) for first-line HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), following promising Phase 1/1b results.

Beyond BCA101, Bicara’s pipeline includes BCA-356, a preclinical bifunctional molecule targeting CAIX and IL-12 to activate localized immune responses. The company is also advancing early-stage discovery programs, including BCA-202, BCA-300, and BCA-400, which reflect its commitment to next-generation, dual-function biologics for solid tumors.

Notable
Articles

Advancing life sciences with expert talent.

(888) 342-2066

Christina@TheElleGrp.com

www.TheElleGrp.com

The Elle Group

The Elle Group

Christina Cagle
Christina Cagle

I am a dedicated advocate for scientific innovation, serving as a strategic partner and collaborator. My mission is to bridge vision with execution, driving breakthroughs that transform lives. Let’s work together to shape a future where science fuels progress and creates a lasting impact.

Christina Cagle, Founder The Elle Group

© 2024 The Elle Group. All Rights Reserved.